Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL11504874 | 0.95 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL167827 | 0.92 | — | — | |
| SCHEMBL30989302 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL19212517 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL30989325 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1246014 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3774795 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL21810763 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL21810753 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3765567 | 0.90 | CA12 (0.43) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170105959-A1 | COMPOSITIONS CONTAINING NITRIC OXIDE AMINO ACID ESTERS AND METHODS FOR IMPROVING SEXUAL PERFORMANCE | SMARTEK INTERNATIONAL, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | FARBER MICHAEL (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150093338-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | FARBER MICHAEL (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946160-B2 | Nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2015-02-03 | — | — | US | disclosed |
| US-8883844-B2 | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions | NITROGENIX INC. (VG) | 2014-11-11 | — | — | US | disclosed |
| US-20140148438-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | NITROGENIX, INC. (VG) | 2014-05-29 | — | — | US | disclosed |
| US-20130287866-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2013-10-31 | — | — | US | disclosed |
| EP-2632453-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR IMPROVING VASCULAR CIRCULATION, AND PROPHYLAXIS OR TREATMENT OF A CONDITION ASSOCIATED WITH IMPAIRED BLOOD CIRCULATION | Oral Delivery Technology Ltd. (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20120289597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-11-15 | — | — | US | disclosed |
| WO-2012088597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR ENHANCEMENT OF PHYSICAL OR MUSCULAR PERFORMANCE AND THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012079146-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR IMPROVING VASCULAR CIRCULATION, AND PROPHYLAXIS OR TREATMENT OF A CONDITION ASSOCIATED WITH IMPAIRED BLOOD CIRCULATION | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012037665-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012027827-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR SKIN REJUVENATION | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011057387-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN | ORAL DELIVERY TECHNOLOGY LTD . (CA) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057386-A1 | COMPOSITION AND PROPHYLACTIC DEVICE FOR ENHANCING SEXUAL PERFORMANCE OR PLEASURE | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202175-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | NOS1, NOS2, NOS3 | CA12 3029/4885CA1 2229/4885CA2 1334/4885 |
| US-20130287866-A1 | Nitric Oxide Amino Acid Esters for Improving Vascular Circulation, and Prophylaxis or Treatment of a Condition Associated with Impaired Blood Circulation | NOS1, NOS2, NOS3 | CA12 2316/4885CA1 2116/4885CA2 1136/4885 |
| US-20140148438-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | NOS2, NOS1, NOS3 | CA12 2305/4885CA1 2425/4885CA2 440/4885 |
| US-20120289597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR THE TREATMENT OF CHRONIC PAIN | NOS2, NOS3, NOS1 | CA12 1144/4885CA1 1120/4885CA2 275/4885 |
| US-20150093338-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER RESPIRATORY CONDITIONS | NOS2, NOS1, NOS3 | CA12 2305/4885CA1 2425/4885CA2 440/4885 |
| US-20170105959-A1 | COMPOSITIONS CONTAINING NITRIC OXIDE AMINO ACID ESTERS AND METHODS FOR IMPROVING SEXUAL PERFORMANCE | NOS1, NOS2, NOS3 | CA12 4112/4885CA1 2920/4885CA2 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.